Here is the summary for GlaxoSmithKline Pharmaceuticals Limited: **Financial Highlights:** GSK Pharma's Q1 FY26 revenue was ₹805 Cr (-0.8% YoY), impacted by General Medicine seasonality.

However, PAT surged 12.7% to ₹205 Cr (25.6% margin). EBITDA grew 9.3% to ₹251 Cr, with margins at 31.2% (+290 bps), driven by improved gross margin and operating leverage. **Strategic Initiatives & Growth Drivers:** Growth is focused on innovation: sharpening GenMed & Paediatric Vaccines strategies, scaling Oncology, and expanding adult immunization via Shingrix (38k Rxs in Q1 FY26, +24% QoQ). Digital engagement is also boosting Healthcare Professional (HCP) reach. **Business Developments:** GSK will launch two Gyn-Oncology brands, Jemperli and Zejula, in India in August 2025, targeting endometrial and ovarian cancers.

The Vaxikart app serviced ~40% of vaccine demand. **Market Position & Competitive Advantage:** GSK maintains strong Vaccines leadership (20.8% unit share in Paediatric Vaccines). Key General Medicine brands also performed competitively.

Consistent performance and profitability gains are noted from portfolio transformation. **Investor Implications:** Despite flat revenue, Q1's strong profitability signals effective cost management.

Upcoming oncology launches and continued specialty/vaccine strength offer positive growth potential.

Investors should watch new product rollout execution closely.